Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He was also appointed to the GSK Board of Directors as an Executive Director and member of the Science Committee.
Hal is responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is a member of the Corporate Executive Team.
Prior to joining GSK in 2018, Hal was President, R&D at Calico (California Life Company). Prior to this, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.
Hal is an Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet, Inc. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.
He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.
Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.